Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581077 | 1.00 | MAPK11 (0.47) | MAPK11MAPK14MAPK13RAF1MAPK9 | |
| SCHEMBL27760173 | 0.83 | CHRM1 (0.39) | MAPK11MAPK14MAPK13RAF1MAPK9 | |
| SCHEMBL3582249 | 0.83 | MPO (0.47) | MAPK11MAPK14MAPK13RAF1MAPK9 | |
| SCHEMBL3582248 | 0.83 | MPO (0.47) | MAPK11MAPK14MAPK13RAF1MAPK9 | |
| SCHEMBL3583291 | 0.80 | ACP1 (0.41) | MPOCHRM1HRH1CHEK1CCNA2 | |
| SCHEMBL3583286 | 0.80 | ACP1 (0.41) | MPOCHRM1HRH1CHEK1CCNA2 | |
| SCHEMBL3582283 | 0.79 | MPO (0.40) | MAPK11MAPK14MAPK13RAF1MAPK9 | |
| Hydrochloric Acid SCHEMBL4599388 | 0.79 | ACP1 (0.40) | MPOCHRM1HRH1CHEK1CCNA2 | |
| SCHEMBL3582287 | 0.79 | MPO (0.40) | MAPK11MAPK14MAPK13RAF1MAPK9 | |
| SCHEMBL20028885 | 0.79 | CHEK1 (0.43) | HTR2AHTR2CDRD2KCNH2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089386-B1 | OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-20100081690-A1 | OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-04-01 | — | — | US | disclosed |
| CN-101558065-A | Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2009-10-14 | — | — | CN | disclosed |
| EP-2089386-A2 | OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008056259-A2 | OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081690-A1 | OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | MAPK11 1500/4885MAPK14 2150/4885MAPK13 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.